References
- Aanouz, I., Belhassan, A., El-Khatabi, K., Lakhlifi, T., El-Ldrissi, M., & Bouachrine, M. (2020). Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations. Journal of Biomolecular Structure and Dynamics, 6, 1–9. https://doi.org/https://doi.org/10.1080/07391102.2020.1758790
- Acter, T., Uddin, N., Das, J., Akhter, A., Choudhury, T. R., & Kim, S. (2020). Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. The Science of the Total Environment, 730, 138996. https://doi.org/https://doi.org/10.1016/j.scitotenv.2020.138996
- Adeoye, A. O., Oso, B. J., Olaoye, I. F., Tijjani, H., & Adebayo, A. I. (2020). Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. Journal of Biomolecular Structure and Dynamics, 15, 1–11. https://doi.org/https://doi.org/10.1080/07391102.2020.1765876
- Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., Ray, A. S., Cihlar, T., Siegel, D., Mackman, R. L., Clarke, M. O., Baric, R. S., & Denison, M. R. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, 9(2), e00221. https://doi.org/https://doi.org/10.1128/mBio.00221-18
- Al-Kofahi, M., Jacobson, P., Boulware, D. R., Matas, A., Kandaswamy, R., Jaber, M. M., Rajasingham, R., Young, J. H., & Nicol, M. R. (2020). Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clinical Pharmacology & Therapeutics, 1–4. https://doi.org/https://doi.org/10.1002/cpt.1874
- Al Saleh, A. S., Sher, T., & Gertz, M. A. (2020). Multiple myeloma in the time of COVID-19. Acta Haematology, 17, 1–7. https://doi.org/https://doi.org/10.1159/000507690000507690
- Ali, I., Alfarouk, K. O., Reshkin, S. J., & Ibrahim, M. E. (2017). Doxycycline as Potential Anti-cancer Agent. Anti-Cancer Agents in Medicinal Chemistry, 17(12), 1617–1623. https://doi.org/https://doi.org/10.2174/1871520617666170213111951
- Andreani, J., Le Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., Wurtz, N., Rolain, J. M., Colson, P., La Scola, B., & Raoult, D. (2020a). In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microbial Pathogenesis, 104228, S0882–S4010. https://doi.org/https://doi.org/10.1016/j.micpath.2020.104228
- Andreani, J., Le Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., Wurtz, N., Rolain, J. M., Colson, P., La Scola, B., & Raoult, D. (2020b). In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microbial Pathogenesis, 145, 104228. https://doi.org/https://doi.org/10.1016/j.micpath.2020.104228
- Asai, A., Konno, M., Ozaki, M., Otsuka, C., Vecchione, A., Arai, T., Kitagawa, T., Ofusa, K., Yabumoto, M., Hirotsu, T., Taniguchi, M., Eguchi, H., Doki, Y., & Ishii, H. (2020). COVID-19 drug discovery using intensive approaches. International Journal of Molecular Sciences, 21(8), 2839. https://doi.org/https://doi.org/10.3390/ijms21082839
- Augustin, M., Hallek, M., & Nitschmann, S. (2020). [Remdesivir for patients with severe COVID-19]. Internist (Berl), 61, 644–645. https://doi.org/https://doi.org/10.1007/s00108-020-00800-5
- Azad, C. S., Saxena, M., Siddiqui, A. J., Bhardwaj, J., Puri, S. K., Dutta, G. P., Anand, N., & Saxena, A. K. (2017). Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents. Chemical Biology & Drug Design, 90(2), 254–261. https://doi.org/https://doi.org/10.1111/cbdd.12944
- Azeem, S., Ashraf, M., Rasheed, M. A., Anjum, A. A., & Hameed, R. (2015). Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pakistan Journal of Pharmaceutical Sciences, 28(2), 597–602.
- Aziz, M., Fatima, R., & Assaly, R. (2020). Elevated interleukin-6 and severe COVID-19: A meta-analysis. Journal of Medical Virology. https://doi.org/https://doi.org/10.1002/jmv.25948
- Babadaei, M. M. N., Hasan, A., Vahdani, Y., Bloukh, S. H., Sharifi, M., Kachooei, E., Haghighat, S., & Falahati, M. (2020). Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. Journal of Biomolecular Structure and Dynamics, 20, 1–9. https://doi.org/https://doi.org/10.1080/07391102.2020.1767210
- Bakheit, A. H., Al-Hadiya, B. M., & Abd-Elgalil, A. A. (2014). Azithromycin. Profiles of Drug Substances, Excipients, and Related Methodology, 39, 1–40. https://doi.org/https://doi.org/10.1016/B978-0-12-800173-8.00001-5
- Baron, S. A., Devaux, C., Colson, P., Raoult, D., & Rolain, J. M. (2020). Teicoplanin: An alternative drug for the treatment of COVID-19? International Journal of Antimicrobial Agents., 55(105944). https://doi.org/https://doi.org/10.1016/j.ijantimicag.2020.105944
- Basit, A., Ali, T., & Rehman, S. U. (2020). Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. Journal of Biomolecular Structure and Dynamics, 20, 1–10. https://doi.org/https://doi.org/10.1080/07391102.2020.1768150
- Beura, S., & Prabhakar, C. (2020). In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 8, 1–25. https://doi.org/https://doi.org/10.1080/07391102.2020.1772111
- Bhardwaj, J., Siddiqui, A. J., Goyal, M., Prakash, K., Soni, A., & Puri, S. K. (2016). Repetitive live sporozoites inoculation under arteether chemoprophylaxis confers protection against subsequent sporozoite challenge in rodent malaria model. Acta Tropica, 158, 130–138. https://doi.org/https://doi.org/10.1016/j.actatropica.2016.02.016
- Bhardwaj, J., Siddiqui, A. J., Goyal, M., Prakash, K., Soni, A., Puri, S. K., & Srivastava, M. (2015). Host immune response is severely compromised during lethal Plasmodium vinckei infection. Parasitology Research, 114(9), 3445–3457. https://doi.org/https://doi.org/10.1007/s00436-015-4570-4
- Bienvenu, A.-L., Marty, A. M., Jones, M. K., & Picot, S. (2020). Systematic review of registered trials of hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. One Health (Amsterdam, Netherlands)), 10, 100141. https://doi.org/https://doi.org/10.1016/j.onehlt.2020.100141
- Boopathi, S., Poma, A. B., & Kolandaivel, P. (2020). Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. Journal of Biomolecular Structure and Dynamics, 30, 1–10. https://doi.org/https://doi.org/10.1080/07391102.2020.1758788
- Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourao, M. P. G., Brito-Sousa, J. D., Baia-da-Silva, D., Guerra, M. V. F., Hajjar, L. A., Pinto, R. C., Balieiro, A. A. S., Pacheco, A. G. F., Santos, J. D. O., Jr., Naveca, F. G., Xavier, M. S., Siqueira, A. M., Schwarzbold, A., … Lacerda, M. V. G, CloroCovid-19 Team (2020). Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Network Open, 3(4), e208857. https://doi.org/https://doi.org/10.1001/jamanetworkopen.2020.8857
- Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S., Wang, F., Liu, J., Chen, L., … Liu, L. (2020). Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering, https://doi.org/https://doi.org/10.1016/j.eng.2020.03.007
- Calderon, J. M., Zeron, H. M., & Padmanabhan, S. (2020). Treatment with hydroxychloroquine vs hydroxychloroquine + nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), 504. https://doi.org/https://doi.org/10.1186/s13063-020-04448-2
- Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. https://doi.org/https://doi.org/10.1016/j.antiviral.2020.104787
- Cao, Y. C., Deng, Q. X., & Dai, S. X. (2020). Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease, 35, 101647. https://doi.org/https://doi.org/10.1016/j.tmaid.2020.101647
- Chaccour, C., Hammann, F., Ramon-Garcia, S., & Rabinovich, N. R. (2020). Ivermectin and novel coronavirus disease (COVID-19): Keeping rigor in times of Urgency. American Journal of Tropical Medicine and Hygiene, 102, 1156–1157. https://doi.org/https://doi.org/10.4269/ajtmh.20-0271
- Chafekar, A., & Fielding, B. C. (2018). MERS-CoV: Understanding the latest human coronavirus threat. Viruses, 10, E93. https://doi.org/https://doi.org/10.3390/v10020093
- Chan, J. F., Lau, S. K., To, K. K., Cheng, V. C., Woo, P. C., & Yuen, K. Y. (2015). Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews, 28(2), 465–522. https://doi.org/10.1128/CMR.00102-14
- Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv. https://doi.org/https://doi.org/10.1101/2020.03.22.20040758
- Choudhary, R., & Sharma, A. K. (2020). Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: Trends, scope and relevance. New Microbes New Infections, 35, 100684. 100684. https://doi.org/https://doi.org/10.1016/j.nmni.2020.100684
- Conforti, C., Giuffrida, R., Zalaudek, I., & Di Meo, N. (2020). Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak. Dermatology and Therapy, e13437. https://doi.org/10.1111/dth.13437
- Cong, Y., Hart, B. J., Gross, R., Zhou, H., Frieman, M., Bollinger, L., Wada, J., Hensley, L. E., Jahrling, P. B., Dyall, J., & Holbrook, M. R. (2018). MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One, 13(3), e0194868. https://doi.org/https://doi.org/10.1371/journal.pone.0194868
- Coomes, E. A., & Haghbayan, H. (2020). Favipiravir, an antiviral for COVID-19? The Journal of Antimicrobial Chemotherapy, 75(7), 2013–2014. https://doi.org/https://doi.org/10.1093/jac/dkaa171
- Costanzo, M., De Giglio, M. A. R., & Roviello, G. N. (2020). SARS-CoV-2: Recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Current Medicinal Chemistry, 27. https://doi.org/https://doi.org/10.2174/0929867327666200416131117
- de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014). Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy, 58(8), 4875–4884. https://doi.org/https://doi.org/10.1128/AAC.03011-14
- de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020). Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of America, 117(12), 6771–6776. https://doi.org/https://doi.org/10.1073/pnas.1922083117
- Delang, L., Abdelnabi, R., & Neyts, J. (2018). Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Research, 153, 85–94. https://doi.org/https://doi.org/10.1016/j.antiviral.2018.03.003
- Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jr., Jahrling, P. B., Laidlaw, M., Johansen, L. M., Lear-Rooney, C. M., Glass, P. J., Hensley, L. E., & Frieman, M. B. (2014). Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy, 58(8), 4885–4893. https://doi.org/https://doi.org/10.1128/AAC.03036-14
- Dyall, J., Gross, R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jr., Hensley, L. E., Frieman, M. B., & Jahrling, P. B. (2017). Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current therapeutic options and potential targets for novel therapies. Drugs, 77(18), 1935–1966. https://doi.org/https://doi.org/10.1007/s40265-017-0830-1
- ECDC. (2020). European Centre for Disease Prevention and Control; https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.
- Elfiky, A. A. (2020). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. Journal of Biomolecular Structure and Dynamics, 6, 1–9. https://doi.org/https://doi.org/10.1080/07391102.2020.1761882
- Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., Benecke, A. G., Katze, M. G., Munster, V. J., & Feldmann, H. (2013). Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nature Medicine, 19(10), 1313–1317. https://doi.org/https://doi.org/10.1038/nm.3362
- Ferner, R. E., & Aronson, J. K. (2020a). Chloroquine and hydroxychloroquine in covid-19. BMJ (Clinical Research ed.).), 369, m1432. https://doi.org/https://doi.org/10.1136/bmj.m1432
- Ferner, R. E., & Aronson, J. K. (2020b). Remdesivir in covid-19. BMJ (Clinical Research ed.).), 369, m1610. https://doi.org/https://doi.org/10.1136/bmj.m1610
- Furuta, Y., Komeno, T., & Nakamura, T. (2017). Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 93(7), 449–463. https://doi.org/https://doi.org/10.2183/pjab.93.027
- Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Dupont, H. T., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J.-M., Brouqui, P., & Raoult, D. (2020a). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949. https://doi.org/https://doi.org/10.1016/j.ijantimicag.2020.105949
- Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Dupont, H. T., Honore, S., Colson, P., Chabriere, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020b). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 105949(20), S0924–S8579. https://doi.org/10.1016/j.ijantimicag.2020.105949
- Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., Sobieszczyk, M. E., & Schluger, N. W. (2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England Journal of Medicine, 382(25), 2411–2418. https://doi.org/https://doi.org/10.1056/NEJMoa2012410
- Gotz, V., Magar, L., Dornfeld, D., Giese, S., Pohlmann, A., Hoper, D., Kong, B. W., Jans, D. A., Beer, M., Haller, O., & Schwemmle, M. (2016). Corrigendum: Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Scientific Reports, 6, 25428. https://doi.org/https://doi.org/10.1038/srep25428
- Gravesen, C., & Judy, J. D. (2020). Effect of biosolids characteristics on retention and release behavior of azithromycin and ciprofloxacin. Environmental Research, 184. https://doi.org/10.1016/j.envres.2020.109333
- Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F. X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., … Flanigan, T. (2020). Compassionate use of remdesivir for patients with severe covid-19. The New England Journal of Medicine, 382(24), 2327–2336. https://doi.org/https://doi.org/10.1056/NEJMoa2007016
- Hart, B. J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Frieman, M. B., Holbrook, M. R., Jahrling, P. B., & Hensley, L. (2014). Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. The Journal of General Virology, 95(Pt 3), 571–577. https://doi.org/https://doi.org/10.1099/vir.0.061911-0
- Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., Shahpasand, K., Saboury, A. A., & Falahati, M. (2020). A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. Journal of Biomolecular Structure and Dynamics, 22, 1–9. https://doi.org/https://doi.org/10.1080/07391102.2020.1754293
- He, T., Yang, W., Zhang, X., Li, P., Yang, D., Wu, Y., Fan, Y., Xiang, M., Huang, Q., Chen, J., Zhou, R., Lv, Q., & Chen, J. (2020). Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Medicine, 99(2), e18550. https://doi.org/https://doi.org/10.1097/MD.0000000000018550
- Hendaus, M. A. (2020). Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): A simplified summary. Journal of Biomolecular Structure and Dynamics, 6, 1–6. https://doi.org/10.1080/07391102.2020.1767691
- Islam, R., Parves, M. R., Paul, A. S., Uddin, N., Rahman, M. S., Mamun, A. A., Hossain, M. N., Ali, M. A., & Halim, M. A. (2020). A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 12, 1–12. https://doi.org/https://doi.org/10.1080/07391102.2020.1761883
- Jalkanen, J., Hollmén, M., & Jalkanen, S. (2020). Interferon beta-1a for COVID-19: Critical importance of the administration route. Crit Care), 24(1), 335. https://doi.org/https://doi.org/10.1186/s13054-020-03048-5
- Jean, S. S., Lee, P. I., & Hsueh, P. R. (2020). Treatment options for COVID-19: The reality and challenges. Journal of Microbiology, Immunology, and Infection = Wei mian yu gan ran za zhi, 53(3), 436–443. https://doi.org/https://doi.org/10.1016/j.jmii.2020.03.034
- Ap, K., S K, T. S., Vs, A., & Tc, V. (2020). Design of multi-epitope vaccine candidate against SARS-CoV-2: A In-Silico study. Journal of Biomolecular Structure and Dynamics, 1, 1–10. https://doi.org/https://doi.org/10.1080/07391102.2020.1770127
- Kelleni, M. T. (2020). Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacological Research, 157(104874), S1043–S6618. https://doi.org/https://doi.org/10.1016/j.phrs2020.104874
- Khan, R. J., Jha, R. K., Amera, G. M., Jain, M., Singh, E., Pathak, A., Singh, R. P., Muthukumaran, J., & Singh, A. K. (2020). Targeting SARS-CoV-2: A systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase. Journal of Biomolecular Structure and Dynamics, 20, 1–14. https://doi.org/10.1080/07391102.2020.1753577
- Lian, N., Xie, H., Lin, S., Huang, J., Zhao, J., & Lin, Q. (2020). Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study. Clinical Microbiology and Infection, 26(20), 917-921. https://doi.org/https://doi.org/10.1016/j.cmi.2020.04.026
- Lin, M. H., Moses, D. C., Hsieh, C. H., Cheng, S. C., Chen, Y. H., Sun, C. Y., & Chou, C. Y. (2018). Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Research, 150, 155–163. https://doi.org/https://doi.org/10.1016/j.antiviral.2017.12.015
- Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6, 16. https://doi.org/https://doi.org/10.1038/s41421-020-0156-0
- Lobo-Galo, N., Terrazas-López, M., Martínez-Martínez, A., & Ág, D.-S. (2020). FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. Journal of Biomolecular Structure and Dynamics, 14, 1–9. https://doi.org/https://doi.org/10.1080/07391102.2020.1764393
- Lu, C. C., Chen, M. Y., Lee, W. S., & Chang, Y. L. (2020). Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association: Jcma, 83(6), 534–536. https://doi.org/https://doi.org/10.1097/JCMA.0000000000000318
- Lu, G., Wang, Q., & Gao, G. F. (2015). Bat-to-human: Spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends in Microbiology, 23(8), 468–478. https://doi.org/https://doi.org/10.1016/j.tim.2015.06.003
- Magagnoli, J., Narendran, S., Pereira, F., Cummings, T., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020). Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv, 2020(04), 16. https://doi.org/https://doi.org/10.1101/2020.04.16.20065920
- Mahanta, S., Chowdhury, P., Gogoi, N., Goswami, N., Borah, D., Kumar, R., Chetia, D., Borah, P., Buragohain, A. K., & Gogoi, B. (2020). Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach. Journal of Biomolecular Structure and Dynamics, 25, 1–10. https://doi.org/https://doi.org/10.1080/07391102.2020.1768902
- Malek, A. E., Granwehr, B. P., & Kontoyiannis, D. P. (2020). Doxycycline as a potential partner of COVID-19 therapies. IDCases, 21, e00864. https://doi.org/https://doi.org/10.1016/j.idcr.2020.e00864
- Mandal, H. (2020). Mobilizing the research ecosystem for scientific advances towards positive impact in the context of the COVID-19 Pandemic. Turkish Journal of Medical Sciences, 50(SI-1), 485–488. https://doi.org/https://doi.org/10.3906/sag-2004-180
- Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de Lamballerie, X., Neyts, J., Hanson, A. M., Frick, D. N., Bolognesi, M., & Milani, M. (2012). Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: New prospects for an old drug. The Journal of Antimicrobial Chemotherapy, 67(8), 1884–1894. https://doi.org/https://doi.org/10.1093/jac/dks147
- Muralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2020). Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular Structure and Dynamics, 16, 1–6. https://doi.org/https://doi.org/10.1080/07391102.2020.1752802
- Murthy, P. K. (2019). Strategies to control human lymphatic filarial infection: Tweaking Host's immune system. Current Topics in Medicinal Chemistry, 19(14), 1226–1240. https://doi.org/https://doi.org/10.2174/1568026619666190618110613
- Pandey, A., Nikam, A. N., Shreya, A. B., Mutalik, S. P., Gopalan, D., Kulkarni, S., Padya, B. S., Fernandes, G., Mutalik, S., & Prassl, R. (2020). Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sciences, 256(117883), S0024–S3205. https://doi.org/10.1016/j.lfs.2020.117883
- Pepperrell, T., Pilkington, V., Owen, A., Wang, J., & Hill, A. M. (2020). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of Virus Eradication, 6(2), 52–60.
- Pshenichnaya, N. Y., Bulgakova, V. A., Lvov, N. I., Poromov, A. A., Selkova, E. P., Grekova, A. I., Shestakova, I. V., Maleev, V. V., & Leneva, I. A. (2019). Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Terapevticheskii Arkhiv, 91(3), 56–63. https://doi.org/https://doi.org/10.26442/00403660.2019.03.000127
- Rabaan, A. A., Al-Ahmed, S. H., Haque, S., Sah, R., Tiwari, R., Malik, Y. S., Dhama, K., Yatoo, M. I., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020). SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Le Infezioni in Medicina, 28(2), 174–184.
- Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., Neary, M., Sharp, J., Liptrott, N. J., Valentijn, A., David, C., Rannard, S. P., Aljayyoussi, G., Pennington, S. H., Hill, A., Boffito, M., Ward, S. A., Khoo, S. H., Bray, P. G., … Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. medRxiv, https://doi.org/10.1101/2020.05.01.20087130
- Roesch, C., Mairet-Khedim, M., Kim, S., Lek, D., Popovici, J., & Witkowski, B. (2020). Impact of the first-line treatment shift from dihydroartemisinin/piperaquine to artesunate/mefloquine on Plasmodium vivax drug susceptibility in Cambodia. Journal of Antimicrobial Chemotherapy, 75, 1766–1771. https://doi.org/https://doi.org/10.1093/jac/dkaa0925811382
- Russell, B., Moss, C., George, G., Santaolalla, A., Cope, A., Papa, S., & Van Hemelrijck, M. (2020). Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience, 14(1022), 1022. https://doi.org/https://doi.org/10.3332/ecancer.2020.1022
- Shea, K. W., & Cunha, B. A. (1995). Teicoplanin. Medical Clinics of North America, 79(4), 833–844. https://doi.org/https://doi.org/10.1016/s0025-7125(16)30042-6
- Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., Bannister, R., Park, Y., Babusis, D., Clarke, M. O., Mackman, R. L., Spahn, J. E., Palmiotti, C. A., Siegel, D., Ray, A. S., Cihlar, T., … Baric, R. S. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine, 9(396), eaal3653. https://doi.org/https://doi.org/10.1126/scitranslmed.aal3653
- Siddiqui, A. J., Bhardwaj, J., Goyal, M., Prakash, K., Adnan, M., Alreshidi, M. M., Patel, M., Soni, A., & Redman, W. (2020). Immune responses in liver and spleen against Plasmodium yoelii pre-erythrocytic stages in Swiss mice model. Journal of Advanced Research, 24, 29–41. https://doi.org/https://doi.org/10.1016/j.jare.2020.02.016
- Siddiqui, A. J., Bhardwaj, J., Goyal, M., Prakash, K., Soni, A., Tiwari, V., & Puri, S. K. (2015). Assessment of real-time method to detect liver parasite burden under different experimental conditions in mice infected with Plasmodium yoelii sporozoites. Microbial Pathogenesis, 89, 35–42. https://doi.org/https://doi.org/10.1016/j.micpath.2015.08.015
- Siddiqui, J. A., Adnan, M., Jahan, S., Redman, W., Saeed, M., & Patel, M. (2020). Neurological disorder and psychosocial aspects of cerebral malaria: What is new on its pathogenesis and complications? A minireview. Folia Parasitologica, 67, 1–10. https://doi.org/https://doi.org/10.14411/fp.2020.015
- Sims, A. C., Burkett, S. E., Yount, B., & Pickles, R. J. (2008). SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Research, 133(1), 33–44. https://doi.org/https://doi.org/10.1016/j.virusres
- Simsek Yavuz, S., & Unal, S. (2020). Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences, 50, 611–619. https://doi.org/https://doi.org/10.3906/sag-2004-145
- Sinha, N., & Balayla, G. (2020). Hydroxychloroquine and covid-19. Postgraduate Medical Journal, 1–6. https://doi.org/https://doi.org/10.1136/postgradmedj-2020-137785
- Soni, A., Goyal, M., Prakash, K., Bhardwaj, J., Siddiqui, A. J., & Puri, S. K. (2015). Cloning, expression and functional characterization of heme detoxification protein (HDP) from the rodent malaria parasite Plasmodium vinckei. Gene, 566(1), 109–119. https://doi.org/https://doi.org/10.1016/j.gene.2015.04.037
- Szolnoky, G. (2020). Further aspects of doxycycline therapy in COVID-19. Dermatology and Therapy, e13810. https://doi.org/10.1111/dth.13810
- Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Gotte, M. (2019). Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses, 11(4), 326. https://doi.org/https://doi.org/10.3390/v11040326
- Thanh Le, T., Andreadakis, Z., Kumar, A., Gomez Roman, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020). The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 19(5), 305–306. https://doi.org/https://doi.org/10.1038/d41573-020-00073-5
- Theoharides, T. C., & Conti, P. (2020). Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents, 34. https://doi.org/10.23812/20-EDITORIAL_1-5
- Wang, Y., Jiang, W., He, Q., Wang, C., Wang, B., Zhou, P., Dong, N., & Tong, Q. (2020). A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduction and Targeted Therapy, 5(1), 57. https://doi.org/https://doi.org/10.1038/s41392-020-0158-2
- WHO. (2020). World Health Organization. Coronavirus disease 2019 (COVID-19) Situation report https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200429-sitrep-100-covid-19.pdf?sfvrsn=bbfbf3d1_2.
- WorldOmeter. (2020). Coronavirus WorldOmeter; https://www.worldometers.info/coronavirus/.
- Wu, R., Wang, L., Kuo, H. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., Poiani, G. J., Amorosa, L., Brunetti, L., & Kong, A. N. (2020). An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports, 6(3), 56–15. https://doi.org/https://doi.org/10.1007/s40495-020-00216-7
- Yaqinuddin, A., & Kashir, J. (2020). Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. Medical Hypotheses, 140, 109777. https://doi.org/https://doi.org/10.1016/j.mehy.2020.109777
- Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., & Zhang, H. (2020). Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. https://doi.org/10.1101/2020.02.05.935387
- Zhang, S., Li, L., Shen, A., Chen, Y., & Qi, Z. (2020). Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig, 40(6), 511–518. https://doi.org/https://doi.org/10.1007/s40261-020-00917-3
- Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6, 14–10. https://doi.org/https://doi.org/10.1038/s41421-020-0153-3
- Zhu, L., Xu, X., Ma, K., Yang, J., Guan, H., Chen, S., Chen, Z., & Chen, G. (2020). Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. American Journal of Transplantation, 20(7), 1859–1863. https://doi.org/https://doi.org/10.1111/ajt.15869
- Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S., & Yuen, K. Y. (2016). Coronaviruses - drug discovery and therapeutic options. Nature Reviews. Drug Discovery, 15(5), 327–347. https://doi.org/https://doi.org/10.1038/nrd.2015.37